News

Explore Latest News .

Find all the latest news on Paul Peter Tak, as well as a comprehensive list of his past interviews and features. Paul Peter’s work in immunology and the pharmaceutical industry has led him to be featured in both business and medicine specific publications.

During his time at GlaxoSmithKline, Paul Peter gave a number of interviews and briefs, including one with the Biochemical Society in 2017. In this insightful interview, Paul Peter outlined what the GSK Immunology Network was and its impact on this important area of research.

In December 2020, Paul Peter Tak spoke with Eleanor Malone, from Scrip, about the work Candel Therapeutics was undertaking in the field of cancer immunotherapy and the companies ambitious future. Paul Peter has also had more broad discussions around his career and what inspires him, such as his interview with Stephanie Sutton for The Medicine Maker, in 2020.   

The Netherlands: ‘Boston by the North Sea?’

Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer

https://www.biospace.com/article/releases/candel-therapeutics-completes-enrollment-in-phase-3-clinical-trial-of-can-2409-in-combination-with-valacyclovir-for-the-treatment-of-intermediate-high-risk-…

A glorious moment, knowing that we have secured the proceeds to deliver on our mission to develop better medicines for patients

My message to the Candel Therapeutics team and stakeholders (patients, collaborators, and investors) in 90 sec

We’re excited to join the @Nasdaq family! Now #NasdaqListed and trading: $CADL. Learn more about our IPO here: https://bit.ly/3i5UcnL

I’m happy to announce that Candel Therapeutics appoints Diem Nguyen, Ph.D., M.B.A., to Its Board of Directors

https://www.businesswire.com/news/home/20210715005303/en/Candel-Therapeutics-Appoints-Diem-Nguyen-Ph.D.-M.B.A.-to-Its-Board-of-Directors

The results of this first-in-human study of CAN-3110 demonstrate a median overall survival that was substantially longer than the six to nine months typically observed in recurrent high-grade glioma as well as a favorable safety profile.

https://www.businesswire.com/news/home/20210604005138/en/Candel-Therapeutics-Announces-Data-from-Phase-1-Trial-of-CAN-3110-in-Recurrent-High-Grade-Glioma-at-the-2021-American-Society-of-Clinical-Onc…

We are delighted to have Carrie Cox join the Candel team and lead our Board of Directors

We are delighted to have Carrie Cox join the Candel team and lead our Board of Directors. Her strategic insights will be key as we advance our late stage pipeline of agents with the potential to bec…
Paul Peter Tak

© Paul Peter Tak.
All rights reserved.